Docetaxel in Combination with Doxorubicin and Cyclophosphamide as Adjuvant Treatment for Early Node-Positive Breast Cancer in the USA: A Cost-Effectiveness and Cost-Utility Analysis

被引：0
|
作者：
Wolowacz, S. E.
Seal, B. S.
Tangirala, M.
机构：
[1] RTI Hlth Solut, Manchester, Lancs, England
[2] Sanofi Aventis Pharmaceut, Bridgewater, NJ USA
[3] Smith Hanley Consulting Grp LLC, Lake Mary, FL USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：622S / 623S
页数：2
相关论文
共 50 条
  • [21] COST-UTILITY MODEL TO EVALUATE ADJUVANT CHEMOTHERAPY FOR EARLY BREAST CANCER IN THE USA
    Wolowacz, S. E.
    Jhaveri, M.
    Tangirala, M.
    VALUE IN HEALTH, 2009, 12 (07) : A279 - A279
  • [22] COST-UTILITY ANALYSIS IN ONCOLOGY - APPLICATION OF ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF NODE POSITIVE PREMENOPAUSAL BREAST-CANCER
    LIVARTOWSKI, A
    POUILLART, P
    M S-MEDECINE SCIENCES, 1992, 8 (10): : 1073 - 1078
  • [23] Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide
    Peng Liubao
    Wan Xiaomin
    Tan Chongqing
    Karnon, Jon
    Chen Gannong
    Li Jianhe
    Cui Wei
    Luo Xia
    Cao Junhua
    PHARMACOECONOMICS, 2009, 27 (10) : 873 - 886
  • [24] Cost-effectiveness analysis of abemaciclib and endocrine therapy combination for the adjuvant treatment of HR+/HER2-, node-positive, high-risk, early breast cancer
    Talwar, Ashna
    Deshmukh, Ashish
    Trivedi, Meghana
    Aparasu, Rajender R.
    CANCER RESEARCH, 2023, 83 (07)
  • [25] Cost-Effectiveness of the 21 Gene Assay in Patients with Node-Positive Breast Cancer
    Fischer, L.
    Arnold, M.
    Kirsch, F.
    Leidl, R.
    GESUNDHEITSWESEN, 2016, 78 (11) : 772 - 780
  • [26] Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer
    Roy, V
    Perez, EA
    CANCER TREATMENT REVIEWS, 2006, 32 (01) : 55 - 58
  • [27] Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal
    Chilcott, J.
    Jones, M. Lloyd
    Wilkinson, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 7 - 13
  • [28] Cost-effectiveness of TAC versus FAC for the treatment of node positive breast cancer in the adjuvant setting
    Fonseca, M.
    Araujo, G.
    Saad, E.
    Uehara, R.
    VALUE IN HEALTH, 2006, 9 (06) : A288 - A288
  • [29] Cost-Effectiveness of 21-Gene Assay in Node-Positive, Early-Stage Breast Cancer
    Vanderlaan, Burton F.
    Broder, Michael S.
    Chang, Eunice Y.
    Oratz, Ruth
    Bentley, Tanya G. K.
    AMERICAN JOURNAL OF MANAGED CARE, 2011, 17 (07): : 455 - 464
  • [30] Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
    Xu, Qiaoping
    Li Yuanyuan
    Zhu Jiejing
    Liu Jian
    Li Qingyu
    Chen Lingya
    Luo Ying
    Shi Changchen
    Li Yangling
    Yan Wei
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)
12345